Next Article in Journal
Antimicrobial, Antibiofilm and Toxicological Assessment of Propolis
Next Article in Special Issue
Treatment of Helicobacter pylori Infection in Patients with Penicillin Allergy
Previous Article in Journal
A Retrospective Study to Compare the Incidence of Hyponatremia after Administration between Linezolid and Tedizolid
Previous Article in Special Issue
Mutations Related to Antibiotics Resistance in Helicobacter pylori Clinical Isolates from Bangladesh
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 2
10.3390/antibiotics12020346
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis

by
Ligang Liu
1,†,
Fang Li
2,†,
Hekai Shi
3 and
Milap C. Nahata
1,4,*
1
Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
2
Department of Pharmacy, Beijing You An Hospital, Capital Medical University, Beijing 100069, China
3
Department of General Surgery, Fudan University Affiliated Huadong Hospital, Shanghai 200040, China
4
Colleges of Pharmacy and Medicine, The Ohio State University, Columbus, OH 43210, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Antibiotics 2023, 12(2), 346; https://doi.org/10.3390/antibiotics12020346
Submission received: 7 December 2022 / Revised: 20 January 2023 / Accepted: 30 January 2023 / Published: 7 February 2023
(This article belongs to the Special Issue Antibiotic Resistance and Therapy for Helicobacter pylori Infection)
Browse Figures
Review Reports Versions Notes

Abstract

:
The eradication of Helicobacter pylori (H. pylori) infection remains challenging due to increasing bacterial resistance. Resistance rates to clarithromycin, metronidazole, and levofloxacin were higher than 30% in the USA, making current therapies less effective. Vonoprazan triple therapy (VAC) has demonstrated similar efficacy and safety profiles compared to PPI-based triple therapy (PPI). However, the eradication rate of vonoprazan dual therapy (VA) for H. pylori infection in comparison to VAC, and PPI was poorly established. Electronic databases were searched up to 6 October 2022, to identify studies examining the safety and efficacy of VA compared to VAC and PPI. Six studies were included. For empiric therapies among treatment naïve patients, VA, VAC, and PPI did not achieve high cure rates (>90%). The comparative efficacy ranking showed VAC was the most effective therapy, followed by VA, and PPI. The results were similar for clarithromycin-resistant infections. The comparative safety ranking showed VA ranked first, whereas PPI triple therapy was the least safe regimen. These findings should guide the selection of the most effective and safe treatment and conduct additional studies to determine the place of vonoprazan dual versus triple therapies in patients with H. pylori from various countries across the world.

1. Introduction

Helicobacter pylori (H. pylori) infection is one of the most common chronic infections across the world. Approximately 50% of the population may test positive for H. pylori infection worldwide [1]. H. pylori infection is associated with chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer [2], which may cost billions of dollars annually in the United States [3].
H. pylori has been classified as a top carcinogen by the World Health Organization (WHO) since 1994 and was listed as a human carcinogen by the U.S. Department of Health and Human Services in 2021 [4,5]. H. pylori infection is the most important modifiable risk factor for preventing gastric cancer, and successful eradication can reduce the risk of gastric cancer [6]. It should be noted that H. pylori infection generally does not disappear spontaneously and may lead to lifelong infection [7]. Thus, medication therapy should be used to eradicate H. pylori to reduce the risk of gastric cancer and decrease the mortality rate [8].
In the US, clarithromycin triple therapy with a proton pump inhibitor (PPI), bismuth quadruple therapy, concomitant therapy, sequential therapy, hybrid therapy, and levofloxacin triple or sequential therapy have been suggested as first-line therapies for the treatment of H. pylori infection [9]. However, the eradication of H. pylori infection remains challenging, notably due to increasing bacterial resistance [10]. Resistance rates to clarithromycin, metronidazole, and levofloxacin were higher than 30% in the USA [11]. Rokkas et al. reported that most PPI-based therapies failed to achieve the desired 90% eradication rate [12]. Some characteristics of PPIs, including short elimination half-lives, insufficient acid suppression, and pharmacokinetic differences among different races, may make PPIs less than an ideal regimen worldwide [13]. Treatment-emergent adverse events can negatively impact adherence, limiting overall efficacy as well [14]. Therefore, an important priority has been to explore new and effective eradication treatments for H. pylori infections.
As a novel potassium-competitive acid blocker (P-CAB), vonoprazan (VPZ) produced a complete acid-inhibition effect with a rapid onset, sustaining pH at the targeted level (6–7) for over 24 h, and undergoing metabolism without CYP2C19 polymorphisms [15]. Vonoprazan has been used for the treatment of H. pylori infection in Japan since 2014 [16]. Vonoprazan-based therapy was the standard therapy in Japanese guidelines [17]. In the Maastricht VI/Florence consensus report, vonoprazan in combination with antibiotics was also recommended as a first-line and second-line treatment, especially in patients with evidence of antimicrobial-resistant infections [18]. Vonoprazan triple therapy has demonstrated comparable or favorable efficacy and safety profiles compared to PPI-based triple therapy [19,20,21,22]. However, the efficacy and safety of vonoprazan dual therapy relative to vonoprazan triple therapy and PPI triple therapy are still unknown. In this network meta-analysis (NWM), we aimed to assess the comparative eradication rate and safety of vonoprazan dual therapy, vonoprazan triple therapy, and PPI triple therapy in adults with H. pylori infection.

2. Method

2.1. Search Strategy and Selection Criteria

This network meta-analysis was performed using the Preferred Reporting Items for Systematic review and Meta-Analysis 2020 (PRISMA) statement [23]. The study protocol was registered on PROSPERO with registration number CRD42022357726. Electronic databases, including PubMed, Embase, Cochrane Library, and Scopus, were searched without any date limitations up to 6 october 2022. The following terms were used to conduct the searches: dual, “Helicobacter pylori”, “H. pylori”, vonoprazan, “potassium-competitive acid blocker”, P-CAB, and TAK-438.
Studies were included in this NWM if they met all criteria: (1) adult diagnosed with H. pylori infection, (2) studies using VPZ-based dual therapy as the interventional group and PPI-based or VPZ-based triple therapies as the control group, and (3) eradication rate included in the outcomes. Studies were excluded if they met any of the following criteria: (1) animal studies, (2) single-arm studies, (3) studies published in languages other than English and Chinese, (4) meta-analysis or systematic review of other studies, (5) review articles, (6) case reports or case series, (7) conference abstracts or journal abstracts.

2.2. Outcome Measures

The primary outcome was the eradication rate based on an intention-to-treat (ITT) analysis and/or per protocol (PP) analysis. Secondary outcomes included dropout rates and commonly reported adverse events.

2.3. Data Extraction and Quality Assessment

Two authors (L.L. and L.F.) independently reviewed all articles by reading the titles and abstracts for eligibility. After screening all articles, two reviewers (L.L. and L.F.) independently extracted the data, including the name of the first author, publication year, country, study design, treatment regimens, duration of treatment, the method used to confirm successful eradication, eradication rate (ITT and/or PP analysis), dropout rate, and adverse events. A third reviewer (M.N.) would be consulted if any disagreement existed.
Treatment regimens were classified into three groups: (1) vonoprazan dual therapy (VA, vonoprazan and amoxicillin), (2) vonoprazan triple therapy (VAC, vonoprazan, amoxicillin, and clarithromycin), and (3) PPI triple therapy (a PPI, amoxicillin, and clarithromycin). Two authors (L.L. and L.F.) independently assessed the risk of bias of the included studies. The Cochrane tool for assessing Risk of Bias in randomized trials version 2 (RoB V.2.0 tool) was used to assess the quality of randomized trials [24]. The quality of cohort studies was assessed using the Newcastle–Ottawa Scale quality instrument. Any disagreements among the first three authors were discussed with the last author (M.N.).

2.4. Data Synthesis and Statistical Analysis

R software (GitHub, San Francisco, CA, USA; version 4.1.2) with the “gemtc” package (version 1.0–1) was used for statistical analysis. The actual cure rates of VPZ-based dual therapy, VPZ-based triple therapy, and PPI-based triple therapy were presented as pooled eradication rates with a 95% confidence interval (95% CI). We compared the following data between the three groups using odds ratios (ORs) with a 95% credible interval (95% CrI): (1) the eradication rate, (2) the dropout rate, (3) the incidence of total adverse events, and (4) each adverse event reported. The I2 test was used to estimate the heterogeneity, and an I2 < 25% indicated low heterogeneity. In all analyses, p < 0.05 (two-tailed) or 95% CrI of OR excluding 1 was considered statistically significant in all analyses. Surface under the cumulative ranking curve (SUCRA) values were used to examine the probability of cumulative ranking. The higher the SUCRA value, the more effective and safer the regimen was. Comparison-adjusted funnel plots were used to examine potential publication biases.

2.5. Subgroup Analysis

We performed several subgroup analyses based upon the duration of treatment (7 days or 14 days), types of studies (clinical trials or observational studies), different amoxicillin doses (1500 mg daily or >1500 mg daily), and the geographic location (Asia or non-Asia).

3. Results

3.1. Study Characteristics and Quality Assessment

A total of 167 studies were identified after a comprehensive literature search. 89 duplicate records were removed. After the title and abstract screening, 56 studies were excluded. 22 studies were reviewed as full text and six studies were included in the final analysis [25,26,27,28,29,30] (Figure 1).
Among 6 studies included, three were conducted in Japan, one in Pakistan, one in the United States and Europe, and one in China. Five studies were randomized clinical trials, with one being a retrospective cohort study. The majority of RCTs were open-label trials. In all studies, 20 mg of vonoprazan was given twice daily to all participants. The amoxicillin dose ranged from 1500 to 3000 mg daily. The dose of clarithromycin was 200 mg twice daily in the studies conducted in Japan, which was in line with the Japanese guidelines for the treatment of H. pylori, and the dose was 500 mg twice daily in studies conducted in other countries. Lansoprazole and omeprazole were the PPIs used in these trials. The duration of therapy was 7 days in most included studies. The urea breath test was used to ensure the successful eradication of H. pylori infection in most studies. Four studies provided the eradication rate in both ITT and PP analyses, and two studies only reported the eradication rate in PP analysis. Therefore, we used the eradication rate from the PP analysis in this NWM. The characteristics of the involved studies are presented in Table 1.
Overall, 1694 patients contributed to the efficacy analysis and 1922 to the safety analysis. In the PP analysis, 750 patients received vonoprazan dual therapy, and the eradication rate was 85.9% (95% CI, 76.5% to 92.0%); 580 patients were in the vonoprazan triple therapy group, and the eradication rate was 87.4% (95%CI, 77.3% to 93.4%); 364 patients had PPI triple therapy, and the eradication rate was 76.5% (95%CI, 65.0% to 85.1%).
The risk of bias evaluation is shown in Table 2. The studies included in this network meta-analysis were of good quality. Overall, all randomized controlled trials had a low risk for bias. The observational study was of good quality, with seven stars.

3.2. Primary Outcome: Efficacy

The network map of the three therapeutic interventions is described in Figure 2. The node size reflected the number of patients who received each treatment. The most common comparison was vonoprazan dual therapy and vonoprazan triple therapy. Compared with PPI triple therapy, vonoprazan dual therapy (OR = 2.04, 95% Crl 1.15 to 4.07) and triple treatment (OR = 2.54, 95% Crl 1.39 to 5.46) showed a significantly higher eradication rate. Vonoprazan dual therapy did not provide greater efficacy than vonoprazan triple therapy (OR = 0.80, 95% Crl 0.49 to 1.29) (Table 3). Judging by SUCRA values, vonoprazan triple therapy (SUCRA = 92.6%) was the best treatment, followed by vonoprazan dual therapy (SUCRA = 56.3%), and PPI-based therapy (SUCRA = 1.1%). The funnel plot of the studies was found to be symmetrical (Figure 3), indicating that there was no publication bias or small sample size study effects.

3.3. Subgroup Analysis

3.3.1. Study Type Effect

To explore the effect of types of studies on the eradication rate, 5 randomized clinical trials were placed as one group. VA therapy was not associated with a higher efficacy (OR = 0.77, 95% Crl 0.43 to 1.30) compared to VAC therapy and had a significantly higher eradication rate than PPI-based triple therapy (OR = 2.04, 95% Crl 1.04 to 4.42) (Table 3).

3.3.2. Treatment Duration Effect

We divided the studies into two groups based on treatment duration. In the 7-day duration group, vonoprazan dual therapy did not show a significantly higher effect than both PPI triple therapy and vonoprazan triple therapy (OR = 2.07, 95% Crl 0.86 to 5.66). In the 14-day group, vonoprazan dual therapy showed a comparable effect to vonoprazan triple therapy (OR = 0.84, 95% Crl 0.38 to 1.75) (Table 3).

3.3.3. Amoxicillin Dose Effect

To explore the effect of amoxicillin daily dose on eradication rate, studies with a total daily dose of 1500 mg versus greater than 1500 mg were placed into two groups. In the high-dose group, vonoprazan dual therapy showed significantly higher efficacy than PPI-based therapy (OR = 2.13, 95% Crl 1.03 to 4.86), and comparative efficacy to vonoprazan triple therapy (OR = 0.85, 95% Crl 0.44 to 1.78). Vonoprazan dual therapy did not offer higher efficacy than vonoprazan triple therapy in the low-dose group as well (OR = 0.71, 95% Crl 0.23 to 2.07) (Table 3).

3.3.4. Regional Effect

Since 5 of 6 studies were conducted in various Asian countries, we grouped the studies from Asia into one group. Vonoprazan dual therapy was not associated with a greater effect than vonoprazan triple therapy (OR = 0.83, 95% Crl 0.38 to 1.68) or PPI triple therapy (OR = 2.86, 95% Crl 0.63 to 13.29) (Table 3).

3.3.5. Efficacy of Clarithromycin-Resistant Strains

Compared with VPZ triple therapy and PPI triple therapy, VPZ dual therapy did not demonstrate higher efficacy (OR = 0.84, 95% Crl 0.55 to 1.31; OR = 1.57, 95% Crl 0.82 to 3.01, separately). Similarly, the rank probability results showed that VPZ triple therapy had the best performance (SUCRA = 89.3%), followed by VPZ dual therapy (SUCRA = 56.3%), and PPI triple therapy (SUCRA = 4.4%).

3.4. Secondary Outcomes

3.4.1. Treatment Discontinuation

Compared with PPI-based triple therapy, a significant difference in discontinuation of therapy was not observed in the VAC group (OR = 1.24, 95% Crl 0.11 to 12.07) and VA group (OR = 1.49, 95% Crl 0.17 to 19.09). VA group did not show a significant difference versus the VAC group as well (OR = 1.21, 95% Crl 0.32 to 6.78) (Table 4). VA had a higher likelihood of discontinuation of therapy (SUCRA = 36.9%) compared to VAC (SUCRA = 51.3%), and PPI triple therapy (SUCRA = 61.8%) (Table 5).

3.4.2. Total Incidence of Adverse Events

Vonoprazan dual therapy was not associated with a lower risk of adverse events compared to vonoprazan triple therapy (OR = 0.69, 95% Crl 0.36 to 1.24), and PPI triple therapy (OR = 0.52, 95% Crl 0.20 to 1.08) (Table 4). Nevertheless, vonoprazan dual therapy had a higher probability of fewer adverse events (SUCRA = 93.8%), followed by vonoprazan triple therapy (SUCRA = 43.3%), and PPI triple therapy (SUCRA = 12.8%) (Table 5).

3.4.3. Diarrhea

Vonoprazan dual therapy had a comparable effect of being associated with diarrhea relative to vonoprazan triple therapy (OR = 0.70, 95% Crl 0.33 to 1.34), and a lower incidence of diarrhea than PPI triple therapy. (OR = 0.36, 95% Crl 0.14 to 0.85) (Table 4). The rank probability results favored VA (SUCRA = 93.1%), followed by VAC (SUCRA = 53.1%), and PPI (SUCRA = 37.4%) (Table 5).

3.4.4. Abdominal Pain

Vonoprazan dual therapy did not have statistically significant differences associated with abdominal pain compared to vonoprazan triple therapy (OR = 1.09, 95% Crl 0.34, 3.52), and PPI-based triple therapy (OR = 0.66, 95% Crl 0.10 to 4.07) (Table 4). Vonoprazan triple therapy showed the best performance (SUCRA = 64.2%), followed by vonoprazan dual therapy (SUCRA = 57.0%), and PPI triple therapy (SUCRA = 28.8%) (Table 5).

3.4.5. Bloating

Vonoprazan dual therapy did not show a lower incidence of bloating compared to vonoprazan triple therapy (OR = 1.48, 95% Crl 0.34 to 6.67), and PPI triple therapy (OR = 0.30, 95% Crl 0.04 to 1.70) (Table 4). The rank probability results favored vonoprazan triple therapy (SUCRA = 83.4%), followed by vonoprazan dual therapy (SUCRA = 59.2%), and PPI triple therapy (SUCRA = 7.50%) (Table 5).

3.4.6. Constipation

Relative to VAC, VA had a comparable effect on the incidence of constipation (OR = 1.76, 95% Crl 0.51 to 7.46) (Table 4). VAC showed a lower risk of constipation (SUCRA = 82.2%) compared to VA (SUCRA = 17.8%) (Table 5).

4. Discussion

Even though H. pylori infection affects billions of individuals worldwide, the best treatment remains uncertain. The increasing resistance to clarithromycin and metronidazole has been alarming, leading to treatment failures [31,32]. Traditional PPI-based triple therapy has been used for decades, and the eradication rate has been reported to be as low as 69.6% [33]. Compared with PPI, vonoprazan has a more potent acid inhibition effect, and a favorable pharmacokinetic profile [34,35]. A previous meta-analysis showed that vonoprazan triple therapy achieved an eradication rate of greater than 90% and exceeded the eradication rate observed with PPI-based therapy [12,19]. However, the efficacy and safety profile of vonoprazan dual therapy compared with other treatments have not been well established.
This network meta-analysis evaluated the efficacy and safety of vonoprazan dual therapy compared with vonoprazan triple therapy and PPI triple therapy. The rank probability results favored vonoprazan triple therapy over other interventions for the eradication rate. Similar trends were observed for clarithromycin-resistant infections. As for safety, the rank probability results demonstrated that VA therapy seemed to decrease the probability of the incidence of total adverse events, diarrhea, and dysgeusia. The administration of broad-spectrum antimicrobials can profoundly damage the structure and decrease the diversity of intestinal microbiota, causing severe diarrhea [36]. Vonoprazan triple therapy was associated with a lower probability of abdominal pain, bloating, constipation, and nausea/vomiting. PPI triple therapy showed a higher likelihood of all adverse effects. It is important to note that vonoprazan dual therapy had a significantly decreased risk of diarrhea compared to the other two regimens, each containing two antibiotics, thus increasing the risk of antibiotic-associated diarrhea [37].
The subgroup analysis revealed that the duration of therapy, types of studies, and regional locations of the included studies did not affect the eradication rate. However, with a higher amoxicillin dose, vonoprazan dual therapy had a greater efficacy outcome than PPI-based therapy. Due to the lack of comparison with PPI triple therapy in the low-dose amoxicillin group, there was not enough evidence to conclude that high-dose amoxicillin may contribute to higher efficacy. However, PPI dual therapy with high-dose amoxicillin has demonstrated significant improvement in efficacy, even higher than 90% [38]. These data emphasize the need to conduct studies to determine the eradication rate with an increased amoxicillin dose in vonoprazan dual therapy.
Graham et al. suggested that the duration of therapy influences the eradication of H. pylori infection [39]. An extended duration may be able to overcome persistent bacteria. A recent systematic review concluded that a prolonged duration of traditional PPI-based triple therapy to 14 days was associated with higher eradication rates [40]. Therefore, 14 days of therapy is the preferred duration over 7 days for certain patients with H. pylori infection.
It is important to note that all participants included in this network meta-analysis were treatment naïve patients. Hu et al. investigated the eradication rate of vonoprazan dual therapy in treatment naïve patients using different doses of amoxicillin and for different durations, and none of the combinations provided an eradication rate greater than 90% [41]. Gotoda et al. also found that in treatment naïve patients, the eradication rate of vonoprazan dual therapy did not reach 90% [42]. Further, a recent meta-analysis showed that the eradication rate of vonoprazan dual therapy was less than 90% [43]. Based on these data, vonoprazan dual therapy may not be preferred as an initial treatment because of the relatively low eradication rate. Gao et al. reported the eradication rate of vonoprazan with 3000 mg amoxicillin daily for 14 days, achieving an eradication rate of 92.5% in patients who had failed previous regimens [44]. This may indicate that the use of vonoprazan and amoxicillin high-dose therapy is preferred in patients with previous treatment failure.
To address the challenges of refractory infections, several strategies may be used to improve the efficacy and safety of treatments. Patient education had positive effects on the H. pylori eradication rate and medication adherence [45]. Probiotics, in conjunction with recommended therapies, slightly increased the eradication rate and significantly decreased the adverse effects of antibiotics [46]. Susceptibility testing may guide the selection of the most effective treatment regimens and improve the eradication rate to exceed 90% [47]. It has been suggested that amoxicillin, clarithromycin, levofloxacin, and metronidazole should be routinely evaluated for H. pylori susceptibility [48,49]. Tailored therapy also had better outcomes than empirical therapy for H. pylori infection [50]. Moreover, vonoprazan-amoxicillin dual therapy with adjustment of amoxicillin dose based on body size may minimize antibiotic resistance development and gut microbiota dysbiosis, while providing the desired efficacy for eradication [51].
It has been suggested that vonoprazan-based triple therapy may contribute to increased global antimicrobial resistance [52]. The use of clarithromycin can drive antibiotic resistance at the population level [53] and would not be effective for the treatment of clarithromycin-resistant infections [54]. Therefore, Suzuki et al. suggested the use of vonoprazan dual therapy because it may provide comparable eradication rates, improve safety and tolerability, and minimize antimicrobial resistance [55]. Moreover, ACG guidelines recommend avoiding clarithromycin in locations where the resistance rate to clarithromycin is greater than 15% [9]. Therefore, before starting vonoprazan triple therapy, the local resistance rate to clarithromycin should be referenced, especially in the US, where the resistance rate exceeds 30%. Ouyang et al. showed that vonoprazan dual therapy had comparable efficacy and safety profiles compared with vonoprazan triple therapy [56]. However, several journal abstracts instead of original articles were included in their meta-analysis, which could have led to potential bias. Further, the optimization of the duration of therapy and the optimal amoxicillin dosing with vonoprazan dual therapy should be studied in future research.
This network meta-analysis has several limitations. Only six studies could be included in this analysis since vonoprazan therapies have not been widely available across the world for substantial time. Most studies were conducted in Asia, with one in the US. Additional studies should be done in Western countries due to geographic differences in antibiotic resistance patterns for H. pylori infection and potential variability in population characteristics. In addition, a comparison between other available treatments, such as bismuth quadruple therapy with vonoprazan dual therapy, has not been performed at this time. Future research should compare regimens with vonoprazan dual therapy and vonoprazan triple therapy to identify the potential use of vonoprazan dual versus triple therapy for the treatment of H. pylori infection.

5. Conclusions

For empiric therapies of H. pylori infection among treatment naïve patients, vonoprazan dual therapy, vonoprazan triple therapy, and PPI triple therapy did not achieve high cure rates (>90%). The comparative efficacy ranking based on SUCRA values showed that vonoprazan triple therapy was the most effective, and PPI triple therapy the least effective regimen. The comparative safety ranking showed that vonoprazan dual therapy was the safest regimen compared to the other two regimens. However, additional clinical trials and real-world studies need to be conducted in Western countries to determine the specific role of vonoprazan dual versus triple therapy based on their relative efficacy and safety in patients with H. pylori infection in various parts of the world.

Author Contributions

Guarantor: M.C.N. is guarantor. He accepts full responsibility for the work and the conduct of the study, had access to the data and controlled the decision to publish. Specific author contributions: L.L. and M.C.N. conceived and drafted the study. L.L. and F.L. collected all data. H.S. and L.L. analyzed and interpreted the data. L.L. and F.L. drafted the manuscript. All authors commented on drafts of the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Matsumoto, H.; Shiotani, A.; Graham, D.Y. Current and future treatment of Helicobacter pylori infections. Adv. Exp. Med. Biol. 2019, 1149, 211–225. [Google Scholar] [PubMed]
  2. Crowe, S.E. Helicobacter pylori infection. N. Engl. J. Med. 2019, 380, 1158–1165. [Google Scholar] [CrossRef] [PubMed]
  3. Peery, A.F.; Crockett, S.D.; Murphy, C.C.; Jensen, E.T.; Kim, H.P.; Egberg, M.D.; Lund, J.L.; Moon, A.M.; Pate, V.; Barnes, E.L.; et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology 2022, 162, 621–644. [Google Scholar] [CrossRef]
  4. International Agency for Research on Cancer. Schistosomes, Liver Flukes and Helicobacter pylori; IARC: Lyon, France, 1994; Volume 61, pp. 1–241. [Google Scholar]
  5. Eight Substances Added to 15th Report on Carcinogens. Available online: https://www.nih.gov/news-events/news-releases/eight-substances-added-15th-report-carcinogens#:~:text=Eight%20substances%20added%20to%2015th%20Report%20on%20Carcinogens,acids%20%28HAAs%29%20found%20as%20water%20disinfection%20byproducts%20 (accessed on 26 October 2022).
  6. Chiang, T.H.; Chang, W.J.; Chen, S.L.; Yen, A.M.; Fann, J.C.; Chiu, S.Y.; Chen, Y.R.; Chuang, S.L.; Shieh, C.F.; Liu, C.Y.; et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut 2021, 70, 243–250. [Google Scholar]
  7. Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global prevalence of Helicobacter pylori infection: Systematic Review and Meta-Analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef]
  8. Sugano, K.; Tack, J.; Kuipers, E.J.; Graham, D.Y.; El-Omar, E.M.; Miura, S.; Haruma, K.; Asaka, M.; Uemura, N.; Malfertheiner, P.; et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015, 64, 1353–1367. [Google Scholar] [CrossRef] [PubMed]
  9. Chey, W.D.; Leontiadis, G.I.; Howden, C.W.; Moss, S.F. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 2017, 112, 212–239. [Google Scholar] [CrossRef] [PubMed]
  10. Savoldi, A.; Carrara, E.; Graham, D.Y.; Conti, M.; Tacconelli, E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization Regions. Gastroenterology 2018, 155, 1372–1382.e17. [Google Scholar] [CrossRef]
  11. Ho, J.J.C.; Navarro, M.; Sawyer, K.; Elfanagely, Y.; Moss, S.F. Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: A systematic review and meta-analysis. Am. J. Gastroenterol. 2022, 117, 1221–1230. [Google Scholar] [CrossRef]
  12. Rokkas, T.; Gisbert, J.P.; Malfertheiner, P.; Niv, Y.; Gasbarrini, A.; Leja, M.; Megraud, F.; O’Morain, C.; Graham, D.Y. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: A network meta-analysis. Gastroenterology 2021, 161, 495–507.e4. [Google Scholar] [CrossRef]
  13. Strand, D.S.; Kim, D.; Peura, D.A. 25 Years of proton pump inhibitors: A comprehensive review. Gut Liver 2017, 11, 27–37. [Google Scholar] [CrossRef] [PubMed]
  14. Zhu, X.Y.; Liu, F. Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy. J. Dig. Dis. 2017, 18, 195–202. [Google Scholar] [CrossRef] [PubMed]
  15. Abdel-Aziz, Y.; Metz, D.C.; Howden, C.W. Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment. Pharmacol. Ther. 2021, 53, 794–809. [Google Scholar]
  16. Garnock-Jones, K.P. Vonoprazan: First global approval. Drugs 2015, 75, 439–443. [Google Scholar] [CrossRef] [PubMed]
  17. Kato, M.; Ota, H.; Okuda, M.; Kikuchi, S.; Satoh, K.; Shimoyama, T.; Suzuki, H.; Handa, O.; Furuta, T.; Mabe, K.; et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter 2019, 24, e12597. [Google Scholar] [CrossRef]
  18. Malfertheiner, P.; Megraud, F.; Rokkas, T.; Gisbert, J.; Liou, J.-M.; Schulz, C.; Gasbarrini, A.; Hunt, R.H.; Leja, M.; O’Morain, C.; et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut 2022, 71, 1724–1762. [Google Scholar] [CrossRef]
  19. Simadibrata, D.M.; Syam, A.F.; Lee, Y.Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2022, 37, 2217–2228. [Google Scholar] [CrossRef]
  20. Shinozaki, S.; Kobayashi, Y.; Osawa, H.; Sakamoto, H.; Hayashi, Y.; Lefor, A.K.; Yamamoto, H. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and meta-analysis. Digestion 2021, 102, 319–325. [Google Scholar] [CrossRef]
  21. Lyu, Q.J.; Pu, Q.H.; Zhong, X.F.; Zhang, J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Biomed Res. Int. 2019, 2019, 9781212. [Google Scholar] [CrossRef]
  22. Liu, L.; Nahata, M.C. Vonoprazan with amoxicillin or amoxicillin and clarithromycin for the treatment of Helicobacter pylori infection. Ann. Pharmacother. 2023, 10600280221149708, epub ahead of print. [Google Scholar] [CrossRef]
  23. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
  24. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomized trials. BMJ 2019, 366, l4898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Furuta, T.; Yamade, M.; Kagami, T.; Uotani, T.; Suzuki, T.; Higuchi, T.; Tani, S.; Hamaya, Y.; Iwaizumi, M.; Miyajima, H.; et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion 2020, 101, 743–751. [Google Scholar] [CrossRef] [PubMed]
  26. Chey, W.D.; Mégraud, F.; Laine, L.; López, L.J.; Hunt, B.J.; Howden, C.W. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology 2022, 163, 608–619. [Google Scholar] [CrossRef]
  27. Horii, T.; Suzuki, S.; Takano, C.; Shibuya, H.; Ichijima, R.; Kusano, C.; Ikehara, H.; Gotoda, T. Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 2021, 36, 3314–3321. [Google Scholar] [CrossRef]
  28. Suzuki, S.; Gotoda, T.; Kusano, C.; Ikehara, H.; Ichijima, R.; Ohyauchi, M.; Ito, H.; Kawamura, M.; Ogata, Y.; Ohtaka, M.; et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicenter randomized trial in Japan. Gut 2020, 69, 1019–1026. [Google Scholar] [CrossRef]
  29. Zuberi, B.F.; Ali, F.S.; Rasheed, T.; Bader, N.; Hussain, S.M.; Saleem, A. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: A randomized control trial. Pak. J. Med. Sci. 2022, 38, 965–969. [Google Scholar] [CrossRef]
  30. Lin, Y.; Xu, H.; Yun, J.; Yu, X.; Shi, Y.; Zhang, D. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: An open, multicenter, randomized clinical study. Ann. Transl. Med. 2022, 10, 987. [Google Scholar] [CrossRef]
  31. Suzuki, S.; Esaki, M.; Kusano, C.; Ikehara, H.; Gotoda, T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J. Gastroenterol. 2019, 25, 1907–1912. [Google Scholar] [CrossRef]
  32. Park, J.Y.; Dunbar, K.B.; Mitui, M.; Arnold, C.A.; Lam-Himlin, D.M.; Valasek, M.A.; Thung, I.; Okwara, C.; Coss, E.; Cryer, B.; et al. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig. Dis. Sci. 2016, 61, 2373–2380. [Google Scholar] [CrossRef]
  33. Shehryar, M.; Ahmad, R.U.; Kareem, H.K.; Khan, L.; Ashraf, M.F.; Hassan, A.; Saeed, S.; Tareen, H.K.; Nazir, D.A.; Ashraf, M.A. Efficacy, safety and cost-effectiveness of vonoprazan vs proton pump inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann. Med. Surg. 2022, 82, 104760. [Google Scholar] [CrossRef] [PubMed]
  34. Kiyotoki, S.; Nishikawa, J.; Sakaida, I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern. Med. 2020, 59, 153–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Miftahussurur, M.; Pratama Putra, B.; Yamaoka, Y. The Potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals 2020, 13, 276. [Google Scholar] [CrossRef] [PubMed]
  36. Vincent, C.; Manges, A.R. Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection. Antibiotics 2015, 4, 230–253. [Google Scholar] [CrossRef] [PubMed]
  37. Baù, M.; Moretti, A.; Bertoni, E.; Vazzoler, V.; Luini, C.; Agosti, M.; Salvatore, S. Risk and protective factors for gastrointestinal symptoms associated with antibiotic treatment in children: A population study. Pediatr. Gastroenterol. Hepatol. Nutr. 2020, 23, 35–48. [Google Scholar] [CrossRef]
  38. Yun, J.; Wu, Z.; Qi, G.; Han, T.; Zhang, D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev. Gastroenterol. Hepatol. 2021, 15, 149–157. [Google Scholar] [CrossRef]
  39. Graham, D.Y.; Shiotani, A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5, 321–331. [Google Scholar] [CrossRef]
  40. Yuan, Y.; Ford, A.C.; Khan, K.J.; Gisbert, J.P.; Forman, D.; Leontiadis, G.I.; Tse, F.; Calvet, X.; Fallone, C.; Fischbach, L.; et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst. Rev. 2013, 12, CD008337. [Google Scholar]
  41. Hu, Y.; Xu, X.; Ouyang, Y.B.; He, C.; Li, N.S.; Xie, C.; Peng, C.; Zhu, Z.H.; Xie, Y.; Shu, X.; et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter 2022, 27, e12896. [Google Scholar] [CrossRef]
  42. Gotoda, T.; Kusano, C.; Suzuki, S.; Horii, T.; Ichijima, R.; Ikehara, H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J. Gastroenterol. 2020, 55, 969–976. [Google Scholar] [CrossRef]
  43. Ouyang, Y.; Wang, M.; Xu, Y.L.; Zhu, Y.; Lu, N.H.; Hu, Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2022, 37, 1666–1672. [Google Scholar] [CrossRef] [PubMed]
  44. Gao, W.; Teng, G.; Wang, C.; Xu, Y.; Li, Y.; Cheng, H. Eradication rate and safety of a “simplified rescue therapy”: 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Helicobacter 2022, 27, e12918. [Google Scholar] [PubMed]
  45. Zha, J.; Li, Y.Y.; Qu, J.Y.; Yang, X.X.; Han, Z.X.; Zuo, X. Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter 2022, 27, e12880. [Google Scholar] [CrossRef] [PubMed]
  46. Penumetcha, S.S.; Ahluwalia, S.; Irfan, R.; Khan, S.A.; Rohit Reddy, S.; Vasquez Lopez, M.E.; Zahid, M.; Busmail, A.; Mohammed, L. The Efficacy of probiotics in the management of Helicobacter pylori: A systematic review. Cureus 2021, 13, e20483. [Google Scholar] [CrossRef] [PubMed]
  47. Li, H.; Shen, Y.; Song, X.; Tang, X.; Hu, R.; Marshall, B.J.; Tang, H.; Benghezal, M. Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing. Helicobacter 2022, 27, e12873. [Google Scholar] [CrossRef]
  48. El-Serag, H.B.; Kao, J.Y.; Kanwal, F.; Gilger, M.; LoVecchio, F.; Moss, S.F.; Crowe, S.E.; Elfant, A.; Haas, T.; Hapke, R.J.; et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin. Gastroenterol. Hepatol. 2018, 16, 992–1002.e6. [Google Scholar] [CrossRef]
  49. Howden, C.W.; Graham, D.Y. Recent developments pertaining to H. pylori Infection. Am. J. Gastroenterol. 2021, 116, 1–3. [Google Scholar] [CrossRef]
  50. Ma, Q.; Li, H.; Liao, J.; Cai, Z.; Zhang, B. Tailored therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Front. Pharmacol. 2022, 13, 908202. [Google Scholar] [CrossRef]
  51. Eto, H.; Suzuki, S.; Kusano, C.; Ikehara, H.; Ichijima, R.; Ito, H.; Kawabe, K.; Kawamura, M.; Yoda, Y.; Nakahara, M.; et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021, 26, e12788. [Google Scholar] [CrossRef]
  52. Graham, D.Y.; Lu, H.; Shiotani, A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J. Gastroenterol. Hepatol. 2021, 36, 1159–1163. [Google Scholar] [CrossRef]
  53. Malhotra-Kumar, S.; Lammens, C.; Coenen, S.; Van Herck, K.; Goossens, H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomized, double-blind, placebo-controlled study. Lancet 2007, 369, 482–490. [Google Scholar] [CrossRef] [PubMed]
  54. Li, M.; Oshima, T.; Horikawa, T.; Tozawa, K.; Tomita, T.; Fukui, H.; Watari, J.; Miwa, H. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter 2018, 23, e12495. [Google Scholar] [CrossRef] [PubMed]
  55. Suzuki, S.; Kusano, C.; Horii, T.; Ichijima, R.; Ikehara, H. The ideal Helicobacter pylori treatment for the present and the future. Digestion 2022, 103, 62–68. [Google Scholar] [CrossRef] [PubMed]
  56. Wang, Z.; Wang, F. Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: A systematic review and meta-analysis. Ther. Adv. Gastroenterol. 2022, 15, 17562848221125308. [Google Scholar] [CrossRef] [PubMed]
Antibiotics 12 00346 g001 550
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow Diagram.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow Diagram.
Antibiotics 12 00346 g001
Antibiotics 12 00346 g002 550
Figure 2. Network of included studies with available direct comparisons. 1. Vonoprazan-amoxicillin; 2. vonoprazan-amoxicillin-clarithromycin; 3. PPI-amoxicillin-clarithromycin.
Figure 2. Network of included studies with available direct comparisons. 1. Vonoprazan-amoxicillin; 2. vonoprazan-amoxicillin-clarithromycin; 3. PPI-amoxicillin-clarithromycin.
Antibiotics 12 00346 g002
Antibiotics 12 00346 g003 550
Figure 3. Comparison−adjusted funnel plot. (A) Adverse events, (B) Efficacy A, Vonoprazan dual therapy; B, vonoprazan triple therapy; C, PPI triple therapy.
Figure 3. Comparison−adjusted funnel plot. (A) Adverse events, (B) Efficacy A, Vonoprazan dual therapy; B, vonoprazan triple therapy; C, PPI triple therapy.
Antibiotics 12 00346 g003
Table
Table 1. Characteristics of studies included in the network meta-analysis.
Table 1. Characteristics of studies included in the network meta-analysis.
Authors (Year, Country)Study DesignNumber Test for Confirming Helicobacter PyloriDuration Eradication RegimenEradication RateCommon Adverse Events
InfectionEradication VAVAC/PPI ITTPP
Furuta et al. (2020, Japan) [25]Retrospective cohort study112RUTUBT7 daysVA: VPZ 20 mg bid, AMO 500 mg tidVAC: VPZ 20 mg, AMO 750 mg, CLA 200 mg, bidVA: 92.9% (52/56), VAC: 91.9% (51/56), p = 0.728VA: 94.4% (51/54), VAC: 92.7% (51/55), p = 0.715Diarrhea: VA (8.9%); VAC (17.8%)
Nausea/vomiting: VA (0%); VAC (1.8%)
Skin rash: VA (3.6%); VAC (0%)
Abdominal pain: VA (1.8%); VAC (3.6%)
Dysgeusia: VA (0%); VAC (1.8%)
Suzuki et al. (2020, Japan) [28]RCT335CUBT7 daysVA: VPZ 20 mg, AMO 750 mg, bidVAC: VPZ 20 mg, AMO 750 mg, CLA 200 mg, bid VA: 84.5% (142/168); VAC: 89.2% (149/167), p = 0.203VA: 87.1% (142/163); VAC: 90.2% (148/164), p = 0.372; CLA-R VA: 92.3%, VAC: 76.2%, p = 0.048Total: VA (27.4%); VAC (30.5%), p = 0.524
Diarrhea: VA (9.5%); VAC (15.0%)
Nausea/vomiting: VA (3.0%); VAC (2.4%)
Skin rash: VA (5.4%); VAC (3.0%)
Abdominal pain: VA (3.6%); VAC (1.2%)
Dysgeusia: VA (1.8%); VAC (1.8%)
Bloating: VA (11.9%); VAC (8.4%)
Horii et al. (2021, Japan) [27]RCT43CC7 daysVA: VPZ 20 mg, AMO 750 mg, bidVAC: VPZ 20 mg, AMO 750 mg, CLA 200 mg, bidN/AVA: 84.2% (16/19); VAC: 95.8% (23/24), p = 0.31Diarrhea: VA (5.3%); VAC (12.5%)
Abdominal pain: VA (5.3%); VAC (0)
Dysgeusia: VA (0); VAC (4.2%)
Skin rash: VA (5.3%); VAC (0)
Nausea: VA (10.5%); VAC (0)
Zuberi et al. (2022, Pakistan) [29]RCT179SAT or Giemsa StainHP Stool Ag14 daysVA: VPZ 20 mg, AMO 1g, bidOAC: OME 20 mg, AMO 1 g, CLA 500 mg, bidN/AVA: 93.5% (86/92); OAC: 83.9% (73/87), p = 0.042Diarrhea: OAC (10.3%); VA (3.3%)
Nausea/vomiting: OAC (14.9%); VA (5.4%)
Bloating: OAC (12.6%), VA (4.3%)
Chey et al. (2022, The United States and Europe) [26]RCT992UBT or biopsyUBT14 daysVA: VPZ 20 mg bid, AMO 1 g tidLAC: LAN 30 mg, AMO 1 g, and CLA 500 mg, bid;
VAC: VPZ 20 mg, AMO 1 g, CLA 500 mg, bid		N-R VA: 78.5% (208/265), LAC: 78.8% (201/255), VAC: 84.7% (222/262);
CLR-R VA: 69.6% (39/ 56), LAC 31.9% (23/ 72), VAC: 65.8% (48/73);
All VA: 77.2% (250/324); LAC: 68.5% (226/330), VAC: 80.8% (273/338)		N-R VA: 81.2% (177/218), LAC: 82.1% (174/212), VAC: 90.4% (198/219);
CLR-R VA: 79.5% (35 /44), LAC: 29.0% (18/62), VAC: 67.2% (39/58);
All VA: 81.1% (215/265), LAC: 70.0% (194/277), VAC: 85.7% (240/280)		Total: VA: (29.9%); LAC (34.5%); VAC (34.1%)
Diarrhea: VA (5.2%); LAC (9.6%); VAC (4.0%)
Headache/dizziness: VA (1.4%); LAC (1.4%); VAC (2.6%)
Dysgeusia: VA (0.6%); LAC (6.1%); VAC (4.3%)
Nausea/vomiting: VA (2.3%); LAC (4.6%); VAC (2.0%)
Abdominal pain: VA (1.4%); LAC (2.0%); VAC (1.2%)
Lin et al. (2022, China) [30]RCT230UBTUBT7 daysH-VA: VPZ 20 mg bid, AMO 750 mg qid
L-VA: VPZ 20 mg bid, AMO 500 mg qid		VAC: VPZ 20 mg, AMO 750 mg, CLA 500 mg, bidH-VA: 63.5% (54/85); L-VA: 58.3% (49/84); VAC: 60.7% (37/61)H-VA: 65.1% (54/83); L-VA: 66.2% (49/74); VAC: 64.9% (37/57)Total: H-VA (16.90%); L-VA (13.20%); VAC (24.10%)
Diarrhea: H-VA (1.2%); L-VA (0); VAC (1.6%)
Abdominal pain: H-VA (2.4%), L-VA (1.2%); VAC (6.6%)
Dizziness: H-VA (2.4%); L-VA (1.2%); VAC (0).
Nausea/vomiting: H-VA (4.7%); L-VA (6.0%); VAC (3.3%)
Skin rash: H-VA (1.2%); L-VA (0); VAC (0)
Abbreviations: RCT, randomized controlled trial; RUT, rapid urease test; C, Culture test; Ag, Anti-H. pylori antibody test; UBT, urea breath test; SAT, stool antigen test; VPZ, vonoprazan; AMO, amoxicillin; CLA, clarithromycin; PPI: proton pump inhibitor; OME: omeprazole; OAC, omeprazole triple therapy; LAC: lansoprazole triple therapy; LAN, lansoprazole; VA, vonoprazan-amoxicillin dual therapy; VAC, vonoprazan-amoxicillin-clarithromycin; triple therapy; H-VA, high-dose amoxicillin combined with VPZ; L-VA, low-dose amoxicillin combined with VPZ; bid, twice daily; tid, three times daily; qid, four times daily; ITT, intention-to-treat; PP, per protocol; N/A, not available, CLR-R: clarithromycin resistant, N-R: without antibiotic-resistant.
Table
Table 2. Assessment of the risk of bias of included RCTs.
Table 2. Assessment of the risk of bias of included RCTs.
AuthorsYearRandomization ProcessDeviations from Intended InterventionsMissing Outcome DataMeasurement of the OutcomeSelection of the Reported ResultOverall Bias
Chey et al. [26]2022Low riskLow riskLow riskLow riskLow riskLow risk
Horii et al. [27]2021Low riskLow riskLow riskLow riskLow riskLow risk
Suzuki et al. [28]2020Low riskLow riskLow riskLow riskLow riskLow risk
Zuberi et al. [29]2022Low riskLow riskLow riskLow riskSome biasLow risk
Lin et al. [30]2022Low riskLow riskLow riskLow riskLow riskLow risk
Table
Table 3. SUCRA-based efficacy ranking league matrix showing the comparative efficacies of the regimens included in this Network Meta-Analysis.
Table 3. SUCRA-based efficacy ranking league matrix showing the comparative efficacies of the regimens included in this Network Meta-Analysis.
Overall
VA1.25 (0.77, 2.06)0.49 (0.25, 0.87)
0.80 (0.49,1.29)VAC0.39 (0.18, 0.72)
2.04 (1.15, 4.07)2.55 (1.39, 5.46)PPI
RCTs
VA1.30 (0.77, 2.33)0.49 (0.23, 0.96)
0.77 (0.49,1.29)VAC0.38 (0.16, 0.76)
2.04 (1.04, 4.42)2.66 (1.32, 6.07)PPI
14-day treatment
VA 1.34 (0.45, 3.96)0.49 (0.18, 1.16)
0.75 (0.25,2.24)VAC0.36 (0.13, 1.03)
2.07 (0.86, 5.66)2.77 (0.97, 7.93)PPI
Asia
VA 1.20 (0.60, 2.64)0.34 (0.08, 1.58)
0.83 (0.38, 1.68)VAC0.29 (0.05, 1.60)
2.86 (0.63, 13.29)3.47 (0.62, 19.93)PPI
High-dose amoxicillin
VA 1.18 (0.56, 2.29)0.47 (0.21, 0.97)
0.85 (0.44,1.78)VAC0.40 (0.17, 092)
2.13 (1.03, 4.86)2.52 (1.09, 5.91)PPI
VA, Vonoprazan dual therapy; VAC, vonoprazan triple therapy; PPI, PPI triple therapy; N/A, not available; RCTs, Randomized controlled trials.
Table
Table 4. SUCRA-based efficacy ranking league matrix showing the comparative safety of the regimens included in this Network Meta-Analysis.
Table 4. SUCRA-based efficacy ranking league matrix showing the comparative safety of the regimens included in this Network Meta-Analysis.
Treatment Discontinuation
VA0.83 (0.15, 3.17)0.67 (0.05, 5.91)
1.21 (0.32, 6.78)VAC0.81 (0.08, 9.01)
1.49 (0.17, 19.09)1.24 (0.11, 12.07)PPI
Incidence of adverse events
VA1.45 (0.81, 2.77)1.92 (0.92, 4.90)
0.69 (0.36, 1.24)VAC1.31 (0.56, 3.61)
0.52 (0.20, 1.08)0.76 (0.28, 1.78)PPI
Diarrhea
VA1.43 (0.75, 3.02)2.79 (1.18, 7.34)
0.70 (0.33, 1.34)VAC1.97 (0.75, 5.22)
0.36 (0.14, 0.85)0.51 (0.19, 1.34)PPI
Abdominal pain
VA0.92 (0.28, 2.95)1.52 (0.25, 9.64)
1.09 (0.34, 3.52)VAC1.68 (0.27, 11.21)
0.66 (0.10, 4.07)0.60 (0.09, 3.65)PPI
Bloating
VA0.68 (0.15, 2.94)3.37 (0.59, 23.29)
1.48 (0.34, 6.67)VAC5.09 (0.52, 56.40)
0.30 (0.04, 1.70)0.20 (0.02, 1.94)PPI
Constipation
VA0.56 (0.13, 1.95)N/A
1.76 (0.51, 7.46)VACN/A
N/AN/APPI
VA, Vonoprazan dual therapy; VAC, vonoprazan triple therapy; PPI, PPI triple therapy; N/A, not available.
Table
Table 5. SUCRA values concerning the safety of therapeutic interventions against Helicobacter pylori included in this Network Meta-Analysis.
Table 5. SUCRA values concerning the safety of therapeutic interventions against Helicobacter pylori included in this Network Meta-Analysis.
VAVACPPI
Treatment discontinuation0.3690.5130.618
Incidence of adverse events0.9380.4330.128
Diarrhea0.9310.5310.374
Abdominal pain0.570.6420.288
Bloating0.5920.8340.075
Constipation0.1780.822N/A
VA, Vonoprazan dual therapy; VAC, vonoprazan triple therapy; PPI, PPI triple therapy; N/A, not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, L.; Li, F.; Shi, H.; Nahata, M.C. The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. Antibiotics 2023, 12, 346. https://doi.org/10.3390/antibiotics12020346

AMA Style

Liu L, Li F, Shi H, Nahata MC. The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. Antibiotics. 2023; 12(2):346. https://doi.org/10.3390/antibiotics12020346

Chicago/Turabian Style

Liu, Ligang, Fang Li, Hekai Shi, and Milap C. Nahata. 2023. "The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis" Antibiotics 12, no. 2: 346. https://doi.org/10.3390/antibiotics12020346

APA Style

Liu, L., Li, F., Shi, H., & Nahata, M. C. (2023). The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. Antibiotics, 12(2), 346. https://doi.org/10.3390/antibiotics12020346

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop